Early Translational Research at UCSF-CTSI: Programs, Plans and Partners

Clinical and TranslationalScience Institute / CTSIat the University of California, San Francisco

Early Translational ResearchJuly 28, 2011

June Lee, MDDirector, Early Translational Research CTSIAssociate Professor, Department of Medicine

Prior experience

• Joined CTSI on 4/26/11

• Title: Director of Early Translational Research

• Prior experience:– 2004-2011 Genentech Inc

• Head of Infectious Diseases, Cardiovascular/ Metabolic Diseases, Respiratory Diseases in Early Clinical Development (Pre-clinical to end of Phase II)

– 1995-2004 UCSF• Pulmonary/Critical Care Faculty• Director of High Risk Asthma Clinic, SFGH• Pulmonary Critical Care Fellow/ Research Fellow

Why now?

• UCSF– Science/scientists– Intent and commitment– Leadership

• External to UCSF– Funding agencies (NIH-NCRR, NCATS)– Regulatory agencies(e.g. FDA)– Industry

Goal: Facilitate/enhance/accelerate earlytranslational research at UCSF

What I’ve been doing

• Listening tour

• Assessing current T1 activities/efforts at UCSF

• Working on a business plan

Translational research

Academia

Start up company/ biotech

Large pharma/company

Academia

Start up company/

biotechLarge

pharma/company

Early (T1) Late (T2)

Bench Bedside Community

Outcomes/ ImpactOutcomes/ Impact BetterHealth

Early translational gaps

• Science to invention

• Invention to product

• Bench to bedside

• Bedside to bench

• Community to bench/ bedside

• Academia to industry

Lead, Influence, Drive…Improve Health

T1 Translational Catalyst Award

• Identify the best projects– Diagnostics, devices, or therapeutics

• Bring in missing pieces– Panels include people from industry and

academics– Panels review and provide individualized feedback

• Leverage limited resources– Identify partnerships if appropriate

Gap: Invention to Product

Phased award approach•Attractiveness•Ease of Implementation•Intellectual Property

Gap: Invention to Product

T1 Catalyst Award program assessment

• Status– Completed 3 cycles of funding to date– Number of proposals submitted was limited– Initial target: “Invention to product” stage but

many proposals were “science to invention” stage

• Feedback– Pilot grants helped advance programs– Customized consulting service very useful

T1 translational catalyst program

Identify & Enable

ScienceInvention

InventionProduct

Gap: Science to Invention, Invention to Product

T1 Translational Award Program

• Planning for multiple tracks– Therapeutics– Diagnostics– Devices– mHealth– Orphan/ rare diseases

Innovative partnerships

• Critical to extending the T1 translational capacity in academia

• Non-traditional models and re-defining the boundaries of private/public partnerships– Pharma/academia– Early stage investors (e.g. Venture capital)– Foundations and venture philanthropy– Others

Near term focus

• Enhancing T1 translational catalyst program

• Build/enhance innovative partnerships to support T1 translational research efforts

• Continue to assess for opportunities– Multidisciplinary cross fertilization

• Bench to bedside• Bedside to bench• Community to bench/bedside

– Education (T1 focused)

• Definition of success

How you can help me

• Please let me know if what has worked well in the past at UCSF and what could work better

• If you’re aware of interesting/successful programs in early translational space, please let me know

• If you have a project/program/issue that CTSI may be able to help with, please call/contact

• Other inputs/perspectives/constructive feedback are all welcome

Accelerate research to improve health

• Identify and address gaps

• Be agile

• Take smart risks

• Collaborate

UCSF SOM/ SON/ SOD/ SOP, CTSI, QB3, NIH, NCATS, Pfizer, Sanofi, Bayer, Genentech/ Roche… many more

THANK YOU!

Questions/Comments415-514-8062

[email protected]